ResoTher Pharma
Clinical-stage biotechnology company based in Copenhagen, Denmark developing peptide-based pro-resolving therapeutics for acute cardiovascular indications. The company has progressed a lead peptide candidate through preclinical development and IND-enabling GLP toxicology, completed a first-in-human Phase I study, initiated a Phase IIa clinical trial in myocardial infarction patients in 2024, and reported top-line Phase IIa results in 2026.
Industries
Nr. of Employees
small (1-50)
ResoTher Pharma
Holte, Capital Region of Denmark, Denmark
Patents
Products
Lead peptide candidate for cardioprotection (RTP-026)
A peptide-based pro-resolving receptor agonist developed to modulate innate immune cell behaviour, reduce neutrophil-driven tissue injury, and promote tissue repair after myocardial infarction. Advanced through preclinical pharmacology and IND-enabling GLP toxicology, evaluated in a first-in-human Phase I study, and progressed to a Phase IIa patient study.
RTP-026
Groundbreaking therapeutic solution by ResoTher Pharma aimed at improving cardiovascular outcomes and treating conditions such as myocardial infarction and ischemia-reperfusion injury.
Lead peptide candidate for cardioprotection (RTP-026)
A peptide-based pro-resolving receptor agonist developed to modulate innate immune cell behaviour, reduce neutrophil-driven tissue injury, and promote tissue repair after myocardial infarction. Advanced through preclinical pharmacology and IND-enabling GLP toxicology, evaluated in a first-in-human Phase I study, and progressed to a Phase IIa patient study.
RTP-026
Groundbreaking therapeutic solution by ResoTher Pharma aimed at improving cardiovascular outcomes and treating conditions such as myocardial infarction and ischemia-reperfusion injury.
Expertise Areas
- Peptide therapeutics development
- Receptor-targeted immunomodulation (FPR2 pathway)
- Cardiovascular drug development and cardioprotection
- Translational pharmacology and preclinical models
Key Technologies
- Peptide-based therapeutics
- Receptor-targeted agonists (FPR2)
- Annexin A1-mimetic mechanism modeling
- Preclinical myocardial infarction models
News & Updates
Announcement that the first patient was dosed in a Phase IIa clinical trial evaluating the lead peptide candidate in myocardial infarction patients.
Company announcement reporting encouraging top-line safety and efficacy signals from a Phase IIa study of the lead peptide cardioprotectant in patients with severe myocardial infarction.
Publication demonstrating that an Annexin A1-mimetic peptide promotes acute cardioprotection through modulation of immune cell activation.
Press release describing completion of a new share issue to expand the investor base and fund preparation for Phase I clinical trials.
Completion of IND-enabling GLP toxicology studies conducted with GLP-certified CROs to support first-in-human studies.
Awarded a €2.5 million grant from the European Innovation Council to support a Phase IIa clinical study of the lead candidate.
Announcement that the first patient was dosed in a Phase IIa clinical trial evaluating the lead peptide candidate in myocardial infarction patients.
Company announcement reporting encouraging top-line safety and efficacy signals from a Phase IIa study of the lead peptide cardioprotectant in patients with severe myocardial infarction.
Publication demonstrating that an Annexin A1-mimetic peptide promotes acute cardioprotection through modulation of immune cell activation.
Press release describing completion of a new share issue to expand the investor base and fund preparation for Phase I clinical trials.
Completion of IND-enabling GLP toxicology studies conducted with GLP-certified CROs to support first-in-human studies.
Awarded a €2.5 million grant from the European Innovation Council to support a Phase IIa clinical study of the lead candidate.